Skip to main content

Advertisement

SpringerLink
Log in

Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Radial basis function artificial neural networks and theoretical descriptors were used to develop a quantitative structure-pharmacokinetic relationship for structurally diverse drug compounds.

Methods. Human bioavailability values were taken from the literature and descriptors were generated from the drug structures. All models were trained with 137 compounds and tested with a further 15, after which they were evaluated for predictive ability with an additional 15 compounds.

Results. The final model possessed a 10-31-1 topology and training and testing correlation coefficients were 0.736 and 0.897, respectively. Predictions for independent compounds agreed well with experimental literature values, especially for compounds that were well absorbed and/or had high observed bioavailability. Important theoretical descriptors included solubility parameters, electronic descriptors, and topological indices.

Conclusions. Useful information regarding drug bioavailability was gained from drug structure alone, reducing the need for experimental methods in drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. G. L. Amidon, P. J. Sinko, and D. Fleisher. Estimating human oral fraction dose absorbed a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5:651-654 (1988).

    Google Scholar 

  2. M. D. Wessel, P. C. Jurs, J. W. Tolan, and S. M. Muskal. Prediction of human intestinal absorption of drug compounds from molecular structure. J. Chem. Inf. Comput. Sci. 38:726-735 (1998).

    Google Scholar 

  3. F. Yoshida and J. G. Topliss. QSAR model for drug human oral bioavailability. J. Med. Chem. 43:2575-2585 (2000).

    Google Scholar 

  4. C. W. Andrews, L. Bennett, and L. X. Yu. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm. Res. 17:639-644 (2000).

    Google Scholar 

  5. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26 (2001).

    Google Scholar 

  6. A. T. Balaban and J. Devillers. Topological Indices and Related Descriptors in QSAR and QSPR, Gordon & Breach, Amsterdam, 1999.

    Google Scholar 

  7. A. Bras, D. Sitar, and F. Aoki. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can. J. Clin. Pharmacol. 8:207-211 (2001).

    Google Scholar 

  8. B. J. Gertz, S. H. Holland, W. F. Kline, B. K. Matuszewski, A. Freeman, H. Quan, K. C. Lasseter, J. C. Mucklow, and A. G. Porras. Studies of the oral bioavailability of alendronate. Clin. Pharmacol. Ther. 58:288-298 (1995).

    Google Scholar 

  9. S. J. Appelbaum, M. Mayersohn, R. T. Dorr, and D. Perrier. Allopurinol kinetics and bioavailability. Intravenous oral and rectal administration. Cancer Chemother. Pharmacol. 8:93-98 (1982).

    Google Scholar 

  10. G. A. Murrell and W. G. Rapeport. Clinical pharmacokinetics of allopurinol. Clin. Pharmacokinet. 11:343-353 (1986).

    Google Scholar 

  11. F. Y. Aoki and D. S. Sitar. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14:35-51 (1988).

    Google Scholar 

  12. M. F. Grayson, A. J. Smith, and R. N. Smith. Absorption distribution and elimination of 14 C-amiloride in normal human subjects. Br. J. Pharmacol. 43:473P-474P (1971).

    Google Scholar 

  13. R. J. Santen and R. I. Misbin. Aminoglutethimide review of pharmacology and clinical use. Pharmacotherapy 1:95-120 (1981).

    Google Scholar 

  14. D. Fausa and K. Rasmussen. Amiodarone-a dangerous wonder drug. Review of the literature and personal experiences. Tidsskr. Nor. Laegeforen. 106:403-406 (1986).

    Google Scholar 

  15. I. Popiliev. Amiodarone pharmacology clinical use and side effects. Vutr. Boles. 24:17-25 (1985).

    Google Scholar 

  16. P. Schulz, K. Turner-Tamiyasu, and G. Smith. Amitriptyline disposition in young and elderly normal men. Clin. Pharmacol. Ther. 33:360-366 (1983).

    Google Scholar 

  17. K. Laine, K. T. Kivistö, I. Laakso, and P. Neuvonen. Prevention of amlodipine absorption by activated charcoal effect of delay in charcoal administration. Br. J. Clin. Pharmacol. 43:29-33 (1997).

    Google Scholar 

  18. K. H. Jones and S. A. Hill. The toxicology absorption and pharmacokinetics of amoxicillin. Adv. Clin. Pharmacol. 7:20(1974).

    Google Scholar 

  19. E. J. Triggs, J. M. Johnson, and B. Learoyd. Absorption and disposition of ampicillin in the elderly. Eur. J. Clin. Pharmacol. 18:195-198 (1980).

    Google Scholar 

  20. N. Muir, J. D. Nichols, M. Stillings, and J. Sykes. The influence of dosage form on aspirin kinetics implications for acute cardiovascular use. Curr. Med. Res. Opin. 13:547-553 (1997).

    Google Scholar 

  21. F. Bochner and J. V. Lloyd. Aspirin for myocardial infarction clinical pharmacokinetic considerations. Clin. Pharmacokinet. 28:433-438 (1995).

    Google Scholar 

  22. M. L. Buck, D. Wiest, and P. C. Gillette. Pharmacokinetics and pharmacodynamics of atenolol in children. Clin. Pharmacol. Ther. 46:629-633 (1989).

    Google Scholar 

  23. D. M. Gibson, N. J. Bron, and A. Richens. Effect of age and gender on pharmacokinetics of atorvastatin in humans. J. Clin. Pharmacol. 36:242-246 (1996).

    Google Scholar 

  24. E. H. Ellinwood, Jr., A. M. Nikaido, S. K. Gupta, D. G. Heatherly, and J. K. Nishita. Comparison of central nervous system and peripheral pharmacodynamics to atropine pharmacokinetics. J. Pharmacol. Exp. Ther. 255:1133-1139 (1990).

    Google Scholar 

  25. K. Tsutsumi, Y. Otsuki, and T. Kinoshita. Simultaneous determination of azathioprine and 6-mercaptopurine in serum by reversed-phase high-performance liquid chromatography. J. Chromatogr. 231:392-399 (1982).

    Google Scholar 

  26. E. W. Wuis, M. J. Dirks, E. F. Termond, T. B. Vree, and E. van der Kleijn. Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur. J. Clin. Pharmacol. 37:181-184 (1989).

    Google Scholar 

  27. J. McAinsh, B. F. Holmes, and N. S. Baber. and J. Young. Bioavailability of propranolol and bendrofluazide formulations. Biopharm. Drug Dispos. 2:167-175 (1981).

    Google Scholar 

  28. M. C. Petersen, R. L. Nation, W. G. McBride, J. J. Ashley, and R. G. Moore. Pharmacokinetics of betamethasone in healthy adults after intravenous administration. Eur. J. Clin. Pharmacol. 25:643-650 (1983).

    Google Scholar 

  29. A. N. de Groot, P. W. van Dongen, and T. B. Vree. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs 56:523-535 (1998).

    Google Scholar 

  30. A. Ward and R. C. Heel. Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 28:426-464 (1984).

    Google Scholar 

  31. R. Mäntylä, P. T. Männistö, A. Vuorela, S. Sundberg, and P. Ottoila. Impairment of captopril bioavailability by concomitant food and antacid intake. Int. J. Clin. Pharmacol. Ther. Toxicol. 22:626-629 (1984).

    Google Scholar 

  32. H. Liu and M. Delgado. Influence of sex, age, weight, and carbamazepine dose on serum concentrations concentration ratios and level/dose ratios of carbamazepine and its metabolites. Ther. Drug Monit. 16:469-476 (1994).

    Google Scholar 

  33. T. Bergan and T. Midtvedt. and J. Erikssen. Human pharmacokinetics of cephalexin. Pharmacology 4:264-272 (1970).

    Google Scholar 

  34. A. Mulhall and J. de Louvois. The monitoring of serum chloramphenicol levels in children with severe infections. J. Antimicrob. Chemother. 16:809-810 (1985).

    Google Scholar 

  35. E. I. Minder. Toxicity in a case of acute and massive overdose of chlordiazepoxide and its correlation to blood concentration. J. Toxicol. Clin. Toxicol. 27:117-127 (1989).

    Google Scholar 

  36. G. I. Adebayo and A. F. Mabadeje. Chlorothiazide absorption in humans-possible example of Michaelis-Menten kinetics. Pharmacology 31:181-188 (1985).

    Google Scholar 

  37. P. R. Farina, T. R. MacGregor, S. T. Horhota, and J. J. Keirns. Relative bioavailability of chlorthalidone in humans after single oral doses. J. Pharm. Sci. 74:995-998 (1985).

    Google Scholar 

  38. J. Lesko, R. Chandrasekharan, and G. L. Amidon. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans correlation with antral gastric motility. Eur. J. Pharm. Biopharm. 53:37-47 (2002).

    Google Scholar 

  39. A. Somogyi and R. Gugler. Clinical pharmacokinetics of cimetidine. Clin. Pharmacokinet. 8:463-495 (1983).

    Google Scholar 

  40. N. Takamatsu, L. S. Welage, Y. Hayashi, R. Yamamoto, J. L. Barnett, V. P. Shah, L. A. Bayer, A. Gajewska, and M. Stephens. Pharmacokinetics of ciprofloxacin in the elderly. Respiration 51:292-295 (1987).

    Google Scholar 

  41. D. M. Campoli-Richards, J. P. Monk, and A. Price. Ciprofloxacin. A review of its antibacterial activity pharmacokinetic properties and therapeutic use. Drugs 35:373-447 (1988).

    Google Scholar 

  42. J. Liliemark. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet. 32:120-131 (1997).

    Google Scholar 

  43. J. D. Panzer, D. C. Brown, W. L. Epstein, R. L. Lipson, H. W. Mahaffey, and W. H. Atkinson. Clindamycin levels in various body tissues and fluids. J. Clin. Pharmacol. New Drugs 12:259-262 (1972).

    Google Scholar 

  44. Y. Sawae and M. Takii. Preclinical and clinical studies of clindamycin-2-phosphate. Jpn. J. Antibiot. 30:42-50 (1977).

    Google Scholar 

  45. G. J. Yakatan, W. J. Poynor, R. L. Talbert, B. F. Floyd, C. L. Slough, R. S. Ampulski, and J. J. Benedict. Clodronate kinetics and bioavailability. Clin. Pharmacol. Ther. 31:402-410 (1982).

    Google Scholar 

  46. H. Naito, M. Wachi, and M. Nishida. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol. Scand. 76:58-63 (1987).

    Google Scholar 

  47. P. Manhem, L. Paalzow, and B. Hökfelt. Plasma clonidine in relation to blood pressure catecholamines and renin activity during long-term treatment of hypertension. Clin. Pharmacol. Ther. 31:445-451 (1982).

    Google Scholar 

  48. G. Nergelius, E. Vinge, H. I. Bengtsson, R. Björkman, and A. Grubb. No effect of diclofenac on the pharmacokinetics of cloxacillin. Pharmacol. Toxicol. 81:26-30 (1997).

    Google Scholar 

  49. S. R. Walker, M. E. Evans, A. J. Richards, and J. W. Paterson. The fate of (14 C)disodium cromoglycate in man. J. Pharm. Pharmacol. 24:525-531 (1972).

    Google Scholar 

  50. M. Colvin and J. Hilton. Pharmacology of cyclophosphamide and metabolites. Cancer Treat. Rep. 65:89-95 (1981).

    Google Scholar 

  51. A. Ahmed and S. Hombal. Cyclophosphamide (Cytoxan(r)). A review on relevant pharmacology and clinical uses. J. Am. Acad. Dermatol. 11:1115-1126 (1984).

    Google Scholar 

  52. M. J. Moore. Clinical pharamcokinetics of cyclophosphamide. Clin. Pharmacokinet. 20:194-208 (1991).

    Google Scholar 

  53. R. L. Capizzi, J. C. White, and B. L. Powell. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin. Hematol. 28:54-69 (1991).

    Google Scholar 

  54. T. R. Brophy, J. McCafferty, and J. H. Tyrer. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur. J. Clin. Pharmacol. 24:103-108 (1983).

    Google Scholar 

  55. M. M. Reidenberg, M. Levy, and H. Warner. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin. Pharmacol. Ther. 23:371-374 (1978).

    Google Scholar 

  56. G. R. Donowitz and G. L. Mandell. Beta-lactam antibiotics. N. Engl. J. Med. 318:419-426 (1988).

    Google Scholar 

  57. D. Faulds and R. N. Brogden. Didanosine: a review of its antiviral activity pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44:94-116 (1992).

    Google Scholar 

  58. C. M. Perry and J. A. Balfour. Didanosine. An update on its antiviral activity, pharmacokinetic properties, and therapeutic efficacy in the management of HIV disease. Drugs 52:928-962 (1996).

    Google Scholar 

  59. C. S. Cook, S. J. McDonald, and A. Karim. Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Xenobiotica 23:1299-1309 (1993).

    Google Scholar 

  60. E. Dempsey, S. Bourque, J. Spenard, and H. Landriault. Pharmacokinetics of single intravenous and oral doses of dolasetron mesylate in healthy elderly volunteers. J. Clin. Pharmacol. 36:903-910 (1996).

    Google Scholar 

  61. J. Heykants, R. Hendriks, W. Meuldermans, M. Michiels, H. Scheygrond, and H. Reyntjens. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur. J. Drug Metab. Pharmacokinet. 6:61-70 (1981).

    Google Scholar 

  62. K. J. Barrington, N. N. Finer, G. Torok-Both, F. Jamali, and R. T. Coutts. Dose-response relationship of doxapram in the therapy for refractory idiopathic apnea of prematurity. Pediatrics 80:22-27 (1987).

    Google Scholar 

  63. D. R. Abernethy and E. L. Todd. Doxepin-cimetidine interaction: Increased doxepin bioavailability during cimetidine treatment. J. Clin. Psychopharmacol. 6:8-12 (1986).

    Google Scholar 

  64. A. Pourtier-Manzanedo, A. Didier, S. Froidevaux, and F. Loor. Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice. Toxicology 99:207-217 (1995).

    Google Scholar 

  65. S. Saivin and G. Houin. Clinical pharmacokinetics of doxycycline and minocycline. Clin. Pharmacokinet. 15:355-366 (1988).

    Google Scholar 

  66. P. A. Todd and K. L. Goa. Enalapril: a reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43:346-381 (1992).

    Google Scholar 

  67. P. A. Todd and P. C. Heel. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypotension and congestive heart failure. Drugs 31:198-248 (1986).

    Google Scholar 

  68. H. J. Gomez, V. J. Cirillo, and J. D. Irvin. Enalapril: a review of human pharmacology. Drugs 30:13-24 (1985).

    Google Scholar 

  69. I. Strauss and F. Erhardt. Ethambutol absorption, excretion and dosage in patients with renal tuberculosis. Chemotherapy 15:148-157 (1970).

    Google Scholar 

  70. J. W. Goldzieher and S. A. Brody. Pharmacokinetics of ethinyl estradiol and mestranol. Am. J. Obstet. Gynecol. 163:2114-2119 (1990).

    Google Scholar 

  71. G. Toffoli, G. Corona, R. Sorio, I. Robieux, B. Basso, A. M. Colussi, and M. Boiocchi. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br. J. Clin. Pharmacol. 52:511-519 (2001).

    Google Scholar 

  72. R. P. Gural, V. S. Chungi, R. P. Shrewsbury, and L. W. Dittert. Dose-dependent absorption of disodium etidronate. J. Pharm. Pharmacol. 37:443-445 (1985).

    Google Scholar 

  73. L. P. James and G. L. Kearns. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin. Pharmacokinet. 31:103-110 (1996).

    Google Scholar 

  74. P. A. Todd and D. Faulds. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs 44:251-277 (1992).

    Google Scholar 

  75. F. E. Simons, J. N. Bergman, W. T. Watson, and K. J. Simons. The clinical pharmacology of fexofenadine in children. J. Allergy Clin. Immunol. 98:1062-1064 (1996).

    Google Scholar 

  76. J. C. Perry and A. Garson, Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am. Heart J. 124:1614-1621 (1992).

    Google Scholar 

  77. B. R. Winkelmann and H. Leinberger. Life-threatening flecainide toxicity. A pharmacodynamic approach. Ann. Intern. Med. 106:807-814 (1987).

    Google Scholar 

  78. S. M. Grant and S. P. Clissold. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 39:877-916 (1990).

    Google Scholar 

  79. C. A. Lyman and T. J. Walsh. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35 (1992).

    Google Scholar 

  80. H. G. Boxenbaum, H. N. Posmanter, T. Macasieb, K. A. Geitner, R. E. Weinfeld, J. D. Moore, A. Darragh, D. A. O'Kelly, L. Weissman, and S. A. Kaplan. Pharmacokinetics of flunitrazepam following single-and multiple-dose oral administration to healthy human subjects. J. Pharmacokin. Biopharm. 6:283-293 (1978).

    Google Scholar 

  81. R. B. Diasio and B. E. Harris. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16:215-237 (1989).

    Google Scholar 

  82. L. A. Jokubaitis. Development and pharmacology of fluvastatin. Br. J. Clin. Pract. 77A:11-15 (1996).

    Google Scholar 

  83. R. E. Cutler, A. W. Forrey, T. G. Christopher, and B. M. Kimpel. Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin. Pharmacol. Ther. 15:588-596 (1974).

    Google Scholar 

  84. L. L. Ponto and R. D. Schoenwald. Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review, Part I. Clin. Pharmacokinet. 18:381-408 (1990).

    Google Scholar 

  85. L. L. Ponto and R. D. Schoenwald. Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review, Part II. Clin. Pharmacokinet. 18:460-471 (1990).

    Google Scholar 

  86. K. L. Goa and E. M. Sorkin. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 46:409-427 (1993).

    Google Scholar 

  87. P. A. Todd and A. Ward. Gemfibrozil: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 36:314-339 (1988).

    Google Scholar 

  88. J. G. Pearson. Pharmacokinetics of glyburide. Am. J. Med. 79:67-71 (1985).

    Google Scholar 

  89. T. L. Schwinghammer, E. J. Antal, R. T. Kubacka, M. E. Hackimer, and J. M. Johnston. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults. Clin. Pharm. 19:532-538 (1991).

    Google Scholar 

  90. W. A. Kradjan, K. A. Kobayashi, L. A. Bauer, J. R. Horn, K. E. Opheim, and F. J. Wood, Jr. Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. J. Clin. Pharmacol. 29:1121-1127 (1989).

    Google Scholar 

  91. W. A. Kradjan, K. Y. Takeuchi, K. E. Opheim, and F. C. Wood, Jr. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 15:465-471 (1995).

    Google Scholar 

  92. E. Wahlin-Boll, L. O. Almer, and A. Melander. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin. Pharmacokinet. 7:363-372 (1982).

    Google Scholar 

  93. P. L. Morselli, G. Bianchetti, and M. Dugas. Haloperidol plasma level monitoring in neuropsychiatric patients. Ther. Drug Monit. 4:51-58 (1982).

    Google Scholar 

  94. T. T. Sproat and L. M. Lopez. Hypertension. In J. C. Delafuente and R. B. Stewart (eds.), Therapeutics in the Elderly, Harvey Whitney Books, Cincinnati, 1995, pp. 228-246.

    Google Scholar 

  95. J. H. Allen, J. M. McKenney, M. A. Stratton, and K. Link. Antihypertensive effect of hydrochlorothiazide administered once or twice daily. Clin. Pharm. 1:239-243 (1982).

    Google Scholar 

  96. N. M. Davies. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin. Pharmacokinet. 34:101-154 (1998).

    Google Scholar 

  97. P. Borchmann, K. Hubel, R. Schnell, and A. Engert. Idarubicin: a brief overview on pharmacology and clinical use. Int. J. Clin. Pharmacol. Ther. 35:80-83 (1997).

    Google Scholar 

  98. L. M. Hollingshead and D. Faulds. Idarubicin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 42:690-719 (1991).

    Google Scholar 

  99. A. Nagy and R. Johansson. Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn-Schmiedebergs Arch. Pharmacol. 290:145-160 (1975).

    Google Scholar 

  100. Mims Australia. Mims Annual. Intercontinental Medical Statistics, Crows Nest NSW, 1999.

  101. P. M. Brooks, M. A. Bell, J. J. Walker, A. C. Kennedy, R. D. Sturrock, and W. C. Dick. Proceedings: ups and downs of indomethacin bioavailability. Ann. Rheum. Dis. 34: (1975).

  102. P. E. Groth and J. M. Dunn. Bioavailability of indomethacin tablets in men volunteers. Clin. Pharm. 5:820-824 (1986).

    Google Scholar 

  103. M. A. Munger and S. M. Furniss. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 16:59S-68S (1996).

    Google Scholar 

  104. J. O. Parker, B. Farrell, K. A. Lahey, and G. Moe. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 316:1440-1444 (1987).

    Google Scholar 

  105. E. Nakashima, J. F. Rigod, E. T. Lin, and L. Z. Benet. Pharmacokinetics of nitroglycerin and its dinitrate metabolites over a thirtyfold range of oral doses. Clin. Pharmacol. Ther. 47:592-598 (1990).

    Google Scholar 

  106. U. W. Abshagen. Pharmacokinetics of isosorbide mononitrate. Am. J. Cardiol. 70:61G-66G (1992).

    Google Scholar 

  107. J. Clements and W. S. Nimmo. Pharmacokinetics and analgesic effect of ketamine in man. Br. J. Anaesth. 53:27-30 (1981).

    Google Scholar 

  108. S. A. Cooper. Ketoprofen in oral surgery pain: a review. J. Clin. Pharmacol. 21:S40-S46 (1988).

    Google Scholar 

  109. E. P. MacCarthy and S. S. Bloomfield. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects. Pharmacotherapy 3:193-219 (1983).

    Google Scholar 

  110. J. J. McNeil and W. J. Louis. Clinical pharmacokinetics of labetalol. Clin. Pharmacokinet. 9:157-167 (1984).

    Google Scholar 

  111. M. A. Johnson, G. A. Verpooten, M. J. Daniel, R. Plumb, J. Moss, D. Vancaesbroeck, and M. E. Debroe. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br. J. Clin. Pharmacol. 46:21-27 (1998).

    Google Scholar 

  112. C. M. Perry and D. Faulds. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 53:657-680 (1997).

    Google Scholar 

  113. A. F. Cohen, G. S. Land, D. D. Breimer, W. C. Yuen, C. Winton, and A. W. Peck. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther. 42:535-541 (1987).

    Google Scholar 

  114. A. Fitton and K. L. Goa. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 50:691-713 (1995).

    Google Scholar 

  115. A. H. Chun, C. J. Eason, H. H. Shi, and J. H. Cavanaugh. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin. Ther. 17:441-447 (1995).

    Google Scholar 

  116. T. T. Doan, Q. Wang, J. S. Griffin, N. L. Lukasik, R. F. O'Dea, and W. J. Pan. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. Am. J. Health Syst. Pharm. 58:1512-1519 (2001).

    Google Scholar 

  117. J. G. Nutt and J. H. Fellman. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 7:35-49 (1984).

    Google Scholar 

  118. L. M. Wing, J. O. Miners, D. J. Birkett, T. Foenander, K. Lillywhite, and S. Wanwimolruk. Lidocaine disposition-sex differences and effects of cimetidine. Clin. Pharmacol. Ther. 35:695-701 (1984).

    Google Scholar 

  119. H. J. Gomez, V. J. Cirillo, and F. Moncloa. The clinical pharmacology of lisinopril. J. Cardiovasc. Pharmacol. 9:S27-S34 (1987).

    Google Scholar 

  120. D. R. Belanger, M. G. Tierney, and G. Dickinson. Effect of sodium polystyrene sulfonate on lithium bioavailability. Ann. Emerg. Med. 21:1312-1325 (1992).

    Google Scholar 

  121. D. J. Greenblatt, M. D. Allen, A. Locniskar, J. S. Harmatz, and R. I. Shader. Lorazepam kinetics in the elderly. Clin. Pharmacol. Ther. 26:103-113 (1979).

    Google Scholar 

  122. H. R. Brunner, Y. Christen, A. Munafo, R. J. Lee, B. Waeber, and J. Nussberger. Clinical experience with angiotensin II receptor antagonists. Am. J. Hypertens. 5:243S-246S (1992).

    Google Scholar 

  123. R. R. Miller and H. Jick. Clinical effects of meperidine in hospitalized medical patients. J. Clin. Pharmacol. 18:180-189 (1978).

    Google Scholar 

  124. B. Bostrom and G. Erdmann. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am. J. Pediatr. Hematol. Oncol. 15:80-86 (1993).

    Google Scholar 

  125. G. B. Elion. Biochemistry and pharmacology of purine analogs. Fed. Proc. 26:898-904 (1967).

    Google Scholar 

  126. T. L. Loo, J. K. Luce, M. P. Sullivan, and E. Frei Iii. Clinical pharmacologic observations on 6-mercaptopurine and 6-methylthiopurine ribonucleoside. Clin. Pharmacol. Ther. 9:180-194 (1968).

    Google Scholar 

  127. C. J. Dunn and D. H. Peters. Metformin: a review of its pharmacologic properties and therapeutic use in diabetes mellitus. Drugs 49:721-749 (1995).

    Google Scholar 

  128. W. A. Bleyer. Clinical pharmacology of intrathecal methotrexate II. An approved dosage regimen derived from age-related pharmacokinetics. Cancer Treat. Rep. 61:1419-1425 (1977).

    Google Scholar 

  129. N. R. Campbell, A. Skerjanec, Y. Tam, S. Robertson, and E. Burgess. Methyldopa kinetics before and after ingestion of methyldopa for eight weeks. Eur. J. Clin. Pharmacol. 48:397-400 (1995).

    Google Scholar 

  130. K. M. Tornatore, G. Logue, R. C. Venuto, and P. J. Davis. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J. Am. Geriatr. Soc. 42:1118-1122 (1994).

    Google Scholar 

  131. K. Lauritsen, L. S. Laursen, and J. Rask-Madsen. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin. Pharmacokinet. 19:11-31 (1990).

    Google Scholar 

  132. E. T. Shore, D. Cepin, and M. J. Davidson. Metoprolol overdose. Ann. Emerg. Med. 10:524-527 (1981).

    Google Scholar 

  133. C. D. Freeman, N. E. Klutman, and K. C. Lamp. Metronidazole. A therapeutic review and update. Drugs 54:679-708 (1997).

    Google Scholar 

  134. J. P. Monk and R. N. Brogden. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. Drugs 40:374-411 (1990).

    Google Scholar 

  135. C. J. Timmer, S. Pourbaix, J. P. Desager, M. Sclavons, and C. Harvengt. Absolute bioavailability of mianserin tablets and solution in healthy humans. Eur. J. Drug Metab. Pharmacokinet. 10:315-323 (1985).

    Google Scholar 

  136. F. P. Meyer. Minocycline for acne. Food reduces minocycline's bioavailability. BMJ 312:1101(1996).

    Google Scholar 

  137. R. P. Walt. Misoprostol for the treatment of peptic ulcer and anti-inflammatory drug-induced gastroduodenal ulceration. N. Engl. J. Med. 327:1575-1580 (1992).

    Google Scholar 

  138. S. F. Brunk and M. Delle. Morphine metabolism in man. Clin. Pharmacol. Ther. 16:51-57 (1974).

    Google Scholar 

  139. H. L. June, M. L. Stitzer, and E. Cone. Acute physical dependence: time course and relation to human plasma morphine concentrations. Clin. Pharmacol. Ther. 57:270-280 (1995).

    Google Scholar 

  140. K. T. Olkkola, K. Hamunen, and E. L. Maunuksela. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin. Pharmacokinet. 28:385-404 (1995).

    Google Scholar 

  141. E. Beyssac, F. Touaref, M. Meyer, L. Jacob, P. Sandouk, and J.-M. Aiache. Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. 19:401-405 (1998).

    Google Scholar 

  142. Anonymous. American academy of pediatrics committee on drugs: naloxone dosage and route of administration for infants and children: addendum to emergency drug doses for infants and children. Pediatrics 86:484-485 (1990).

  143. M. A. Hussain, C. A. Koval, M. J. Myers, E. G. Shami, and E. Shefter. Improvement of the oral bioavailability of naltrexone in dogs: a prodrug approach. J. Pharm. Sci. 76:356-358 (1987).

    Google Scholar 

  144. R. E. Ferner, S. Monkman, J. Riley, S. Cholerton, J. R. Idle, and D. N. Bateman. Pharmacokinetics and toxic effects of nifedipine in massive overdose. Hum. Exp. Toxicol. 9:309-311 (1990).

    Google Scholar 

  145. E. A. Ramoska, H. A. Spiller, and A. Myers. Calcium channel blocker toxicity. Ann. Emerg. Med. 19:649-653 (1990).

    Google Scholar 

  146. H. R. Ochs, D. J. Greenblatt, R. Gugler, G. Müntefering, A. Locniskar, and D. R. Abernethy. Cimetidine impairs nitrazepam clearance. Clin. Pharmacol. Ther. 34:227-230 (1983).

    Google Scholar 

  147. J. T. Callaghan, R. F. Bergstrom, A. Rubin, S. Chernish, R. Crabtree, M. P. Knadler, B. Obermeyer, W. W. Offen, D. W. Schneck, and G. Aronoff. A pharmacokinetic profile of nizatidine in man. Scand. J. Gastroenterol. Suppl. 136:9-17 (1987).

    Google Scholar 

  148. R. Vargas, J. Ryan, F. G. McMahon, G. Regel, W. W. Offen, and C. Matsumoto. Pharmacokinetics and pharmacodynamics of oral nizatidine. J. Clin. Pharmacol. 28:71-75 (1988).

    Google Scholar 

  149. I. Nilsson-Ehle and B. Ljungberg. Quinolone disposition in the elderly: practical implications. Drugs Aging 1:279-288 (1991).

    Google Scholar 

  150. E. E. Kvist, A. Al-Shurbaji, M. L. Dahl, C. Nordin, G. Alvan, and L. Stahle. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin. Pharmacokinet. 40:869-877 (2001).

    Google Scholar 

  151. B. Lipper and B. D. Gaynor. Value of serum tricyclic antidepressant levels with massive nortriptyline overdose and persistent hypotension. Am. J. Emerg. Med. 13:107(1995).

    Google Scholar 

  152. S. Dawling, P. Crome, and R. Braithwaite. Pharmacokinetics of single oral doses of nortriptyline in depressed elderly hospital patients and young healthy volunteers. Clin. Pharmacokinet. 5:394-401 (1980).

    Google Scholar 

  153. T. Andersson. Omeprazole drug interaction studies. Clin. Pharmacokinet. 21:195-212 (1991).

    Google Scholar 

  154. F. Massoomi, J. Savage, and C. J. Destache. Omeprazole: a comprehensive review. Pharmacotherapy 13:46-59 (1993).

    Google Scholar 

  155. F. Roila and A. Del Favero. Ondansetron clinical pharmacokinetics. Clin. Pharmacokinet. 29:95-109 (1995).

    Google Scholar 

  156. K. H. Simpson and F. M. Hicks. Clinical pharmaco-kinetics of ondansetron: a review. J. Pharm. Pharmacol. 48:774-781 (1996).

    Google Scholar 

  157. M. W. Jann, T. L. ZumBrunnen, S. N. Tenjarla, E. S. Ward, Jr., and D. J. Weidler. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy 18:288-294 (1998).

    Google Scholar 

  158. B. J. Chaffee and R. M. Tankanow. Ondansetron-the first of a new class of antiemetic agents. Clin. Pharm. 10:430-436 (1991).

    Google Scholar 

  159. S. E. Leucuta, M. Follidis, R. Capalneanu, and A. Mocan. Relative bioavailability of different oral sustained release oxprenolol tablets. Eur. J. Drug Metab. Pharmacokinet. 23:178-184 (1998).

    Google Scholar 

  160. E. Kalso and A. Vainio. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin. Pharmacol. Ther. 47:639-646 (1990).

    Google Scholar 

  161. A. Fitton and D. McTavish. Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318 (1991).

    Google Scholar 

  162. R. Huber, M. Hartmann, H. Bliesath, R. Luhmann, V. W. Steinijans, and K. Zech. Pharmacokinetics of pantoprazole in man. Int. J. Clin. Pharmacol. Ther. 34:S7-16 (1996).

    Google Scholar 

  163. N. Muir, J. D. Nichols, J. M. Clifford, M. R. Stillings, and R. Hoare. Comparative bioavailability of aspirin and paracetamol following single dose administration of soluble and plain tablets. Curr. Med. Res. Opin. 13:491-500 (1997).

    Google Scholar 

  164. W. J. Shih, J. Fong, and M. L. Gora. Meperidine in conjunction with cholescintigraphy to diagnose acute cholecystitis in a patient allergic to morphine. Clin. Nucl. Med. 19:981-984 (1994).

    Google Scholar 

  165. R. Gugler, C. V. Manion, and D. L. Azarnoff. Phenytoin: pharmacokinetics and bioavailability. Clin. Pharmacol. Ther. 19:135-142 (1992).

    Google Scholar 

  166. N. P. Chau, Y. A. Weiss, M. E. Safar, D. E. Lavene, D. R. Georges, and P. L. Milliez. Pindolol availability in hypertensive patients with normal and impaired renal function. Clin. Pharmacol. Ther. 22:505-510 (1977).

    Google Scholar 

  167. D. McTavish and E. M. Sorkin. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 42:65-89 (1991).

    Google Scholar 

  168. H. Mikami and T. Ogihara. Therapeutic drug monitoring of alpha-blocker, prazosin. Jpn. J. Clin. Med. 48:1143-1144 (1990).

    Google Scholar 

  169. P. A. Reece. Quantification of prazosin in plasma by high-performance liquid chromatography. J. Chromatogr. 221:188-192 (1980).

    Google Scholar 

  170. G. Rostock, H. D. Faulhaber, P. Unger, V. Homuth, C. Prehm, and R. Günzel. Comparative study of the relative bioavailabilities of two prazosin preparations in patients with essential hypertension. Pharmazie 40:259-261 (1985).

    Google Scholar 

  171. S. Watanabe, C. Kuyama, S. Yokoyama, S. Kubo, and H. Iwai. Distribution of plasma phenobarbital, diphenylhydantoin and primidone levels in epileptic patients. Folia Psychiatr. Neurol. Jap. 31:205-217 (1977).

    Google Scholar 

  172. H. E. Booker, K. Hosokowa, R. D. Burdette, and B. Darcey. A clinical study of serum primidone levels. Epilepsia 11:395-402 (1970).

    Google Scholar 

  173. J. Koch-Weser. Serum procainamide levels as therapeutic guides. Clin. Pharmacokinet. 2:389-402 (1977).

    Google Scholar 

  174. R. A. Tokola. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 8:139-147 (1988).

    Google Scholar 

  175. T. L. Schwinghammer, R. P. Juhl, L. W. Dittert, S. K. Melethil, F. J. Kroboth, and V. S. Chung. Comparison of the bioavailability of oral, rectal and intramuscular promethazine. Biopharm. Drug Dispos. 5:185-194 (1984).

    Google Scholar 

  176. S. G. Barnwell, S. J. Burns, S. Higginbottom, I. Whelan, D. Corness, G. Hay, E. Rosenberg, and D. Attwood. Demonstration of the importance of biphasic oleic acid delivery for enhancing the bioavailability of propranolol in healthy volunteers. Int. J. Pharm. 128:145-154 (1996).

    Google Scholar 

  177. C. G. Duarte, A. C. Polizello, A. I. Assis-Pandochi, and A. C. Spadaro. Optimization of HPLC analysis for the determination of propylthiouracil levels in plasma and serum. J. Pharm. Biomed. Anal. 23:237-241 (2000).

    Google Scholar 

  178. A. M. Horvath, D. Pilon, G. Caillé, W. A. Colburn, J. J. Ferry, G. J. Frank, Y. Lacasse, and S. C. Olson. Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quin and its active metabolite (quinat). Biopharm. Drug Dispos. 11:191-196 (1990).

    Google Scholar 

  179. C. N. Verme, T. M. Ludden, W. A. Clementi, and S. C. Harris. Pharmacokinetics of quinidine in male patients. A population analysis. Clin. Pharmacokinet. 22:468-480 (1992).

    Google Scholar 

  180. J. Kindler, H. Schunkert, M. Gassmann, W. Lahn, R. Irmisch, E. R. Debusmann, J. Ocón-Pujadas, E. Ritz, and H. G. Sieberth. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure. J. Cardiovasc. Pharmacol. 13:S55-S58 (1989).

    Google Scholar 

  181. S. M. Grant, H. D. Langtry, and R. N. Brogden. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 37:801-870 (1989).

    Google Scholar 

  182. D. F. Smee, R. W. Sidwell, B. B. Barnett, and R. S. Spendlove. Bioassay system for determining ribavirin levels in human serum and urine. Chemotherapy 27:1-11 (1981).

    Google Scholar 

  183. G. Gatti, N. Barzaghi, G. Attardo Parrinello, B. Vitiello, and E. Perucca. Pharmacokinetics of salicylic acid following administration of aspirin tablets and three different forms of soluble aspirin in normal subjects. Int. J. Clin. Pharmacol. Res. 9:385-389 (1989).

    Google Scholar 

  184. F. Trebini, D. Daniele, S. Gillio, and L. Scarzella. Clinical evaluation of selegiline (L-deprenyl) in the long-term L-dopa treatment syndrome. Acta Neurol. Scand. 7:432-439 (1985).

    Google Scholar 

  185. M. N. Gordon, C. D. Muller, K. A. Sherman, D. G. Morgan, A. J. Azzaro, and L. Wecker. Oral versus transdermal selegiline: antidepressant-like activity in rats. Pharmacol. Biochem. Behav. 63:501-506 (1999).

    Google Scholar 

  186. E. Grau, M. Perella, and E. Pastor. Simvastatin-oral anticoagulant interaction. Lancet 347:405-6 (1996).

    Google Scholar 

  187. A. Fitton and E. M. Sorkin. Sotalol: an updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias. Drugs 46:678-719 (1993).

    Google Scholar 

  188. P. Kahela, M. Anttila, R. Tikkanen, and H. Sundquist. Effect of food, food constituents and fluid on the bioavailability of sotalol. Acta Pharmacol. Toxicol. 44:7-12 (1979).

    Google Scholar 

  189. W. R. Bartle, P. E. Coates, M. M. Fisher, and F. J. Louman. Effect of neomycin on the bioavailability of spironolactone: a single-dose study. Am. J. Hosp. Pharm. 36:1701-1703 (1979).

    Google Scholar 

  190. E. B. Lewin, J. O. Klein, and M. Finland. Trimethoprim-sulfamethoxazole: absorption, excretion, and toxicity in six children. J. Infect. Dis. 128:S618-S621 (1973).

    Google Scholar 

  191. E. R. Garrett, R. S. Süverkrup, K. Eberst, R. L. Yost, and J. P. O'Leary. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm. Drug Dispos. 2:329-365 (1981).

    Google Scholar 

  192. V. F. Cosson and E. Fuseau. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. J. Pharmacokin. Biopharm. 27:149-171 (1999).

    Google Scholar 

  193. P. E. Warner, K. L. Brouwer, E. K. Hussey, G. E. Dukes, W. D. Heizer, K. H. Donn, I. M. Davis, and J. R. Powell. Sumatriptan absorption from different regions of the human gastrointestinal tract. Pharm. Res. 12:138-143 (1995).

    Google Scholar 

  194. W. J. Krall, J. J. Sramek, and N. R. Cutler. Cholinesterase inhibitors: a therapeutic strategy for alzheimer disease. Ann. Pharmacother. 33:441-450 (1999).

    Google Scholar 

  195. P. D. Kroboth, R. B. Smith, R. Rault, M. R. Silver, M. I. Sorkin, J. B. Puschett, and R. P. Juhl. Effects of end-stage renal disease and aluminum hydroxide on temazepam kinetics. Clin. Pharmacol. Ther. 37:453-459 (1985).

    Google Scholar 

  196. H. E. Hosie and W. S. Nimmo. Temazepam absorption in patients before surgery. Br. J. Anaesth. 66:20-24 (1991).

    Google Scholar 

  197. L. Borgström, C. X. Liu, and A. Walhagen. Pharmacokinetics of the enantiomers of terbutaline after repeated oral dosing with racemic terbutaline. Chirality 1:174-177 (1989).

    Google Scholar 

  198. U. Täuber, K. Schröder, B. Düsterberg, and H. Matthes. Absolute bioavailability of testosterone after oral administration of testosterone-undecanoate and testosterone. Eur. J. Drug Metab. Pharmacokinet. 11:145-149 (1986).

    Google Scholar 

  199. K. S. Albert, R. D. Welch, K. A. De Sante, and A. R. Di Santo. Decreased tetracycline bioavailability caused by a bismuth subsalicylate antidiarrheal mixture. J. Pharm. Sci. 68:586-588 (1979).

    Google Scholar 

  200. P. A. Kramer, D. J. Chapron, J. Benson, and S. A. Mercik. Tetracycline absorption in elderly patients with achlorhydria. Clin. Pharmacol. Ther. 23:467-472 (1978).

    Google Scholar 

  201. N. Rojanasthien, K. Kovjiriyapan, M. Manorot, and C. Pothirat. Comparative steady-state bioavailability of sustained-release theophylline preparations: Theo-Dur, Uni-Dur and Xanthium. Asian Pac. J. Allergy Immunol. 19:69-78 (2001).

    Google Scholar 

  202. S. Massa, G. Stefancich, M. Artico, F. Corelli, G. C. Pantaleoni, G. Palumbo, D. Fanini, and R. Giorgi. Non-steroidal anti-inflammatory agents. IV. Synthesis and pharmacologic activity of aroylthiopheneacetic acids with a pyrrole group. Farmaco 41:281-291 (1986).

    Google Scholar 

  203. R. Sutinen, P. Paronen, V. Saano, and A. Urtti. Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation. Eur. J. Pharm. Sci. 11:25-31 (2000).

    Google Scholar 

  204. E. J. Antal, W. R. Gillespie, J. P. Phillips, and K. S. Albert. The effect of food on the bioavailability and pharmacodynamics of tolbutamide in diabetic patients. Eur. J. Clin. Pharmacol. 22:459-462 (1982).

    Google Scholar 

  205. W. Mühlberg, E. Mutschler, A. Hofner, H. Spahn-Langguth, and O. Arnold. The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study. Arch. Gerontol. Geriatr. 32:265-273 (2001).

    Google Scholar 

  206. V. Heimsoth, D. Loew, and O. Schuster. Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene. Eur. J. Drug Metab. Pharmacokinet. 13:161-164 (1988).

    Google Scholar 

  207. R. L. Williams, J. Mordenti, R. A. Upton, E. T. Lin, W. L. Gee, C. D. Blume, and L. Z. Benet. Effects of formulation and food on the absorption of hydrochlorothiazide and triamterene or amiloride from combination diuretic products. Pharm. Res. 4:348-352 (1987).

    Google Scholar 

  208. H. Klinker, P. Langmann, M. Zilly, and E. Richter. Drug monitoring during the treatment of AIDS-associated pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole. J. Clin. Pharm. Therap. 23:149-154 (1998).

    Google Scholar 

  209. T. Meshi and Y. Sato. Studies on sulfamethoxazole-trimethoprim. Absorption, distribution, excretion and metabolism of trimethoprim in rat. Chem. Pharm. Bull. 20:2079-2090 (1972).

    Google Scholar 

  210. G. Caillé, J. G. Besner, Y. Lacasse, and M. Vézina. Pharmacokinetic characteristics of two different formulations of trimipramine determined with a new GLC method. Biopharm. Drug Dispos. 1:187-194 (1980).

    Google Scholar 

  211. F. Kees, L. Farber, M. Bucher, G. Mair, K. Morike, and H. Grobecker. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. Br. J. Clin. Pharmacol. 52:705-707 (2001).

    Google Scholar 

  212. R. Davis, D. H. Peters, and D. McTavish. Valproic acid: a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47:332-372 (1994).

    Google Scholar 

  213. D. McTavish. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38:19-76 (1989).

    Google Scholar 

  214. F. O. Müller, J. M. Steyn, H. K. Hundt, and H. G. Luus. Warfarin bio-availability. A comparison of 4 products. S. Afr. Med. J. 74:566-567 (1988).

    Google Scholar 

  215. J. M. Adams, M. J. Shelton, R. G. Hewitt, M. DeRemer, R. Di Francesco, T. H. Grasela, and G. D. Morse. Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob. Agents Chemother. 42:409-413 (1998).

    Google Scholar 

  216. A. Guarino, F. Albano, A. Castaldo, M. I. Spagnuolo, and R. B. Canani. Intestinal malabsorption and zidovudine bioavailability. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18:91-92 (1998).

    Google Scholar 

  217. I. Gutman, O. Miljkovi, G. Caporossi, and P. Hansen. Alkanes with small and large Randic connectivity indices. Chem. Phys. Lett. 306:366-372 (1999).

    Google Scholar 

  218. L. B. Kier and L. H. Hall. Molecular Connectivity in Chemistry and Drug Research, Academic Press, New York, 1976.

    Google Scholar 

  219. M. Randic. Novel shape descriptors for molecular graphs. J. Chem. Inf. Comput. Sci. 41:607-613 (2001).

    Google Scholar 

  220. J. Galvez, R. Garciadomenech, V. Dejulianortiz, and R. Soler. Topological approach to analgesia. J. Chem. Inf. Comput. Sci. 34:1198-1203 (1994).

    Google Scholar 

  221. N. Trinajstic. Chemical Graph Theory, CRC Press, Boca Raton, 1992.

    Google Scholar 

  222. F. Burden. A chemically intuitive molecular index based on the eigenvalues of a modified adjacency matrix. Quant. Struct.-Act. Relat. 16:309-314 (1997).

    Google Scholar 

  223. R. O. Potts and R. H. Guy. The influence of molecular volume and hydrogen-bonding on peptide transport across epithelial membranes. Pharm. Res. 10:635-637 (1993).

    Google Scholar 

  224. M. Genty, G. González, C. Clere, V. Desangle-Gouty, and J. Y. D. Legendre. Determination of the passive absorption through the rat intestine using chromatographic indices and molar volume. Eur. J. Pharm. Sci. 12:223-229 (2001).

    Google Scholar 

  225. C. Hansch. Substituent Constants for Correlation Analysis in Chemistry and Biology, Umi Research Press, New York, 1979.

    Google Scholar 

  226. V. N. Viswanadhan, A. K. Ghose, G. R. Revankar, and R. K. Robins. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J. Chem. Inf. Comput. Sci. 29:163-172 (1989).

    Google Scholar 

  227. N. Bodor and P. Buchwald. Octanol-water partition searching for predictive models. Curr. Med. Chem. 5:353-380 (1998).

    Google Scholar 

  228. Z. Meng and W. R. Carper. Effects of hydration on the molecular structure of metal ion-atrazine dimer complexes a MOPAC (PM3) study. J. Mol. Struct. Theochem. 531:89-98 (2000).

    Google Scholar 

  229. P. Ertl, B. Rohde, and P. Selzer. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43:3714-3717 (2000).

    Google Scholar 

  230. G. Klopman and H. Zhu. Estimation of the aqueous solubility of organic molecules by the group contribution approach. J. Chem. Inf. Comput. Sci. 41:439-445 (2001).

    Google Scholar 

  231. G. C. Cash and R. G. Clements. Comparison of structure-activity relationships derived from two methods for estimating octanol-water partition coefficients. SAR QSAR Environ. Res. 5:113-124 (1996).

    Google Scholar 

  232. G. Klopman, C. M. Ding, and O. T. Macina. Computer aided olive oil-gas partition coefficient calculations. J. Chem. Inf. Comput. Sci. 37:569-575 (1997).

    Google Scholar 

  233. R. Reed. Pruning algorithms—a survey. IEEE Trans. Neural Netw. 4:740-747 (1993).

    Google Scholar 

  234. E. Derks, M. S. S. Pastor, and L. M. C. Buydens. Robustness analysis of radial base function and multi-layered feed-forward neural network models. Chem. Intell. Lab. Syst. 28:49-60 (1995).

    Google Scholar 

  235. S. Winiwarter, N. M. Bonham, F. Ax, A. Hallberg, H. Lennernas, and A. Karlen. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41:4939-4949 (1998).

    Google Scholar 

  236. K. Palm. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14:568-571 (1997).

    Google Scholar 

  237. R. B. Hermann. Modeling hydrophobic solvation of nonspherical systems comparison of use of molecular surface area with accessible surface area. J. Comput. Chem. 18:115-125 (1997).

    Google Scholar 

  238. N. Bodor and M. J. Huang. A new method for the estimating of the aqueous solubility of organic compounds. J. Pharm. Sci. 81:954-960 (1992).

    Google Scholar 

  239. T. Ooi, M. Oobatake, G. Némethy, and H. A. Scheraga. Accessible surface areas as a measure of the thermodynamic parameters of hydration of peptides. Proc. Natl. Acad. Sci. USA 84:3086-3090 (1987).

    Google Scholar 

  240. W. J. Dunn III, M. G. Koehler, and S. Grigoras. The role of solvent-accessible surface area in determining partition coefficients. J. Med. Chem. 30:1121-1126 (1987).

    Google Scholar 

  241. S. O. Shan and D. Herschlag. The change in hydrogen bond strength accompanying charge rearrangement-implications for enzymatic catalysis. Proc. Natl. Acad. Sci. USA 93:14474-14479 (1996).

    Google Scholar 

  242. J. A. Mennella and G. K. Beauchamp. The transfer of alcohol to human milk. Effects on flavor and the infant's behavior. N. Engl. J. Med. 325:981-985 (1991).

    Google Scholar 

  243. S. Bhattacharjee and P. Dasgupta. Molecular property correlation in alkanes with geometric volume. Comput. Chem. 18:61-71 (1994).

    Google Scholar 

  244. D. Gorse, A. Rees, M. Kaczorek, and R. Lahana. Molecular diversity and its analysis. Drug Discov. Today 4:257-264 (1999).

    Google Scholar 

  245. L. H. Hall and L. B. Kier. Design of molecules from quantitative structure-activity relationship models. 3. Role of higher order path counts path three. J. Chem. Inf. Comput. Sci. 33:598-603 (1993).

    Google Scholar 

  246. E. Estrada. Generalization of topological indices. Chem. Phys. Lett. 336:248-252 (2001).

    Google Scholar 

  247. M. J. Kogan, K. Verebey, and S. J. Mule. Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration. Res. Commun. Chem. Pathol. Pharmacol. 18:29-34 (1977).

    Google Scholar 

  248. M. C. Meyer, A. B. Straughn, M. W. Lo, W. L. Schary, and C. C. Whitney. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J. Clin. Psych. 45:15-19 (1984).

    Google Scholar 

  249. J. V. Turner, D. J. Cutler, I. Spence, and D. J. Maddalena. Selective descriptor pruning for QSAR/QSPR studies using artificial neural networks. J. Comput. Chem.

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia

    Joseph V. Turner

  2. Department of Pharmacology, Faculty of Medicine, The University of Sydney, Sydney, Australia

    Desmond J. Maddalena

  3. Centre for Pharmaceutical Research, School of Pharmaceutical, Molecular and Biomedical Sciences, University of South Australia, Adelaide, Australia

    Snezana Agatonovic-Kustrin

Authors
  1. Joseph V. Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Desmond J. Maddalena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Snezana Agatonovic-Kustrin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph V. Turner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turner, J.V., Maddalena, D.J. & Agatonovic-Kustrin, S. Bioavailability Prediction Based on Molecular Structure for a Diverse Series of Drugs. Pharm Res 21, 68–82 (2004). https://doi.org/10.1023/B:PHAM.0000012154.09631.26

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:PHAM.0000012154.09631.26

Search

Navigation